Sales & Marketing News | pharmaphorum

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Texas sues Sanofi, claiming kickbacks to doctors

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.

News

Hims & Hers buys Australian digital health firm for $1.15bn

Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by buying Eucalyptus Health.

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

Texas sues Sanofi, claiming kickbacks to doctors

Hims & Hers buys Australian digital health firm for $1.15bn

AI specialist Chai Discovery raises $400m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks